Increased mutations in Env and Pol suggest greater HIV-1 replication in sputum-derived viruses compared with blood-derived viruses

AIDS

Volumn 23, Issue 8, 2009, Pages 923-928

  Wagner, Thor A ^a,b   Tobin, Nicole H ^a,b   McKeman, Jennifer L ^b   Xu, Min ^a,b   Melvin, Ann J ^a,b   Mohan, Kathleen M ^a   Learn, Gerald H ^a   Mullins, James I ^a   Frenkel, Lisa M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Drug resistance; HAART; HIV 1; Lung; Macrophages; Replication; Sputum; Virus

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; LOPINAVIR PLUS RITONAVIR; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENVELOPE PROTEIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SCHOOL CHILD; SPUTUM; VIRUS REPLICATION;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; GENES, ENV; GENES, POL; HIV INFECTIONS; HIV-1; HUMANS; PLASMA; RNA, VIRAL; SPUTUM; VIRUS REPLICATION;

EID: 67049156200     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328329f964     Document Type: Article

References (37)

1. Gallant JE, Dejesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
2. BartlettJA, Fath MJ, Demasi R, Hermes A, QuinnJ, Mondou E, Rousseau F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-2064.
3. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, et al. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 2000; 6:76-81.
4. Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002; 76:707-716.
5. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, Curlin ME, et al. HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest 2005; 115:3250-3255.
6. Tobin NH, Learn GH, Holte SE, Wang Y, Melvin AJ, McKernan JL, et al. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus. J Virol 2005; 79:9625-9634.
7. + T cells. J Virol 2006; 80:6441-6457.
8. Persaud D, Ray SC, Kajdas J, Ahonkhai A, Siberry GK, Ferguson K, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23:381-390.
9. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000; 6:82-85.
10. Chun TW, Davey RT Jr, Ostrowski M, Justement SJ, Engel D, Mullins Jl, Fauci AS. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy. Nat Med 2000; 6:757-761.
11. Zhang L, Chung C, Hu BS, He T, Guo Y, Kim AJ, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000; 106:839-845.
12. Dybul M, Daucher M, Jensen MA, Hallahan CW, Chun TW, Belson M, et al. Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy. j Virol 2003; 77:3229-3237.
13. + T cell depletion and viral replication in SIV infection. Science 1998; 280:427-431.
14. + T cells. Nature 2005; 434:1148-1152.
15. + T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093- 1097.
16. Guadalupe M, Sankaran S, George MD, Reay E, Verhoeven D, Shacklett BL, et al. Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1 -infected patients initiating therapy during primary or chronic infection. J Virol 2006; 80:8236-8247.
17. Belmonte L, Olmos M, Fanin A, Parodi C, Baré P, Concetti H, et al. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART. AIDS 2007; 21:2106-2108.
18. Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, et al. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS 2007; 21:1849-1854.
19. Richman DD, Kornbluth RS, Carson DA. Failure of dideoxy-nucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med 1987; 166: 1144-1149.
20. PernoCF, SvicherV, ScholsD, PollicitaM, BalzariniJ, AquaroS. Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res 2006; 71:293-300.
21. Crowe S, Zhu T, Muller WA. The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol 2003; 74:635-641.
22. Itescu S, Simonelli PF, Winchester RJ, Ginsberg HS. Human immunodeficiency virus type 1 strains in the lungs of infected individuals evolve independently from those in peripheral blood and are highly conserved in the C-terminal region of the envelope V3 loop. Proc Natl Acad Sci U S A 1994; 91: 11378-11382.
23. Nakata K, Weiden M, Harkin T, Ho D, Rom WN. Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-1-infected patients: evidence for genetic differences in HIV-1 between lung and blood macro-phage populations. Mol Med 1995; 1:744-757.
24. Atkins M, StrappeP, KayeS, LovedayC, McLaughlinJE, Johnson MA, et al. Quantitative differences in the distribution of zidovudine resistance mutations in multiple postmortem tissues from AIDS patients. J Med Virol 1998; 55:138-146.
25. White NC, Israel-Biet D, Coker RJ, Mitchell DM, Weber JN, Clarke JR. Different resistance mutations can be detected simultaneously in the blood and the lung of HIV-1 infected individuals on antiretroviral therapy. J Med Virol 2004; 72:352-357.
26. Stebbing J, Gazzard B, Douek DC. Where does HIV live? N Engl j Med 2004; 350:1872-1880.
27. Payord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997; 52:498-501.
28. Rodrigo AG, Goracke PC, Rowhanian K, Mullins Jl. Quantita-tion of target molecules from polymerase chain reaction-based limiting dilution assays. AIDS Res Hum Retrovir 1997; 13:73 7-742.
29. Jensen MA, van 'tWout AB. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev 2003; 5:104-112.
30. Frenkel LM, Wang Y, Learn GH, McKernan JL, Ellis GM, Mohan KM, et al. Multiple viral genetic analyses detecting low-level HIV-1 replication during effective HAART. J Virol 2003; 77:5721-5730.
31. RuffCT, RaySC, Kwon P, Zinn R, Pendleton A, Hutton N, et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002; 76:9481-9492.
32. Shankarappa R, MargolickJB, GangeSJ, Rodrigo AG, Upchurch D, Farzadegan H, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999; 73:10489-10502.
33. Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, et al. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007; 21:721-732.
34. Abel K, Rocke DM, Chohan B, Fritts L, Miller CJ. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79:12164-12172.
35. Lewin SR, Kirihara J, Sonza S, Irving L, Mills J, Crowe SM. HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals. AIDS 1998; 12:719-727.
36. Brenchley J, Knox K, Asher A, Price DA, Kohli LM, Gostick E, et al. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol 2008; 1:49-58.
37. Twigg HL, Weiden M, Valentine F, Schnizlein-Bick CT, Bassett R, Zheng L, et al. Effect of highly active antiretroviral therapy on viral burden in the lungs of HIV-infected subjects. J Infect Dis 2008; 197:109-116.